How to buy Calliditas Therapeutics AB publ stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Calliditas Therapeutics AB publ stock

Own Calliditas Therapeutics AB publ stock in just a few minutes.

Calliditas Therapeutics AB (publ) is a drug manufacturers-specialty & generic business based in the US. Calliditas Therapeutics AB publ shares (CALT) are listed on the NASDAQ and all prices are listed in US Dollars. Calliditas Therapeutics AB publ employs 34 staff and has a market cap (total outstanding shares value) of USD$690.8 million.

How to buy shares in Calliditas Therapeutics AB publ

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Calliditas Therapeutics AB publ. Find the stock by name or ticker symbol: CALT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Calliditas Therapeutics AB publ reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Calliditas Therapeutics AB publ, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Calliditas Therapeutics AB publ. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Calliditas Therapeutics AB publ share price

Use our graph to track the performance of CALT stocks over time.

Calliditas Therapeutics AB publ shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$19 - USD$36.1
50-day moving average USD$28.4802
200-day moving average USD$29.8585
Wall St. target priceUSD$49.6
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.1935

Buy Calliditas Therapeutics AB publ shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Calliditas Therapeutics AB publ stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Calliditas Therapeutics AB publ financials

Gross profit TTM USD$874,000
Return on assets TTM -19.75%
Return on equity TTM -42.7%
Profit margin 0%
Book value N/A
Market capitalisation USD$690.8 million

TTM: trailing 12 months

Shorting Calliditas Therapeutics AB publ shares

There are currently 22,932 Calliditas Therapeutics AB publ shares held short by investors – that's known as Calliditas Therapeutics AB publ's "short interest". This figure is 4.6% down from 24,030 last month.

There are a few different ways that this level of interest in shorting Calliditas Therapeutics AB publ shares can be evaluated.

Calliditas Therapeutics AB publ's "short interest ratio" (SIR)

Calliditas Therapeutics AB publ's "short interest ratio" (SIR) is the quantity of Calliditas Therapeutics AB publ shares currently shorted divided by the average quantity of Calliditas Therapeutics AB publ shares traded daily (recently around 14332.5). Calliditas Therapeutics AB publ's SIR currently stands at 1.6. In other words for every 100,000 Calliditas Therapeutics AB publ shares traded daily on the market, roughly 1600 shares are currently held short.

However Calliditas Therapeutics AB publ's short interest can also be evaluated against the total number of Calliditas Therapeutics AB publ shares, or, against the total number of tradable Calliditas Therapeutics AB publ shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calliditas Therapeutics AB publ's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Calliditas Therapeutics AB publ shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Calliditas Therapeutics AB publ shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Calliditas Therapeutics AB publ.

Find out more about how you can short Calliditas Therapeutics AB publ stock.

Calliditas Therapeutics AB publ share dividends

We're not expecting Calliditas Therapeutics AB publ to pay a dividend over the next 12 months.

Calliditas Therapeutics AB publ share price volatility

Over the last 12 months, Calliditas Therapeutics AB publ's shares have ranged in value from as little as $19 up to $36.1. A popular way to gauge a stock's volatility is its "beta".

CALT.US volatility(beta: 1.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calliditas Therapeutics AB publ's is 1.5346. This would suggest that Calliditas Therapeutics AB publ's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Calliditas Therapeutics AB publ overview

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site